Core Insights - BridgeBio Pharma, Inc. announced the presentation of long-term efficacy and safety data for acoramidis in patients with ATTR-CM at the ACC Annual Scientific Sessions & Expo [1] - The company will present a late-breaking oral presentation and three posters detailing additional findings from the open-label extension trial [2] Group 1: Presentation Details - The late-breaking oral presentation titled "Long-Term Survival Benefits and Disease Stabilization with Acoramidis in Patients with ATTR-CM" will be presented by Dr. Prem Soman on March 30, 2026 [2] - Three posters will cover various aspects of acoramidis treatment, including its effects on serum transthyretin concentrations and health status related to heart failure [2] Group 2: Product Information - Attruby™ (acoramidis) is indicated for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM) in adults, aiming to reduce cardiovascular death and related hospitalizations [3] Group 3: Safety Information - Adverse reactions reported for Attruby include diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo), with most being mild and resolving without discontinuation [4]

Key Takeaways Alnylam reported $2.99B in 2025 net product revenues, up 81% YoY, driven by four approved drugs.ALNY's cemdisiran hit key phase III endpoints in generalized MG, with partner Regeneron planning U.S. filing.Zilebesiran and mivelsiran advance in late and mid-stage studies, targeting cardiovascular and AD markets.Alnylam Pharmaceuticals (ALNY) currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together generated $2.99 billion in net product revenues, representin ...

Core Viewpoint - BridgeBio's stock surged due to a favorable ruling in the patent dispute involving Pfizer's tafamidis, which is crucial for its competitive positioning in the market [1] Group 1: Patent Dispute and Market Impact - A judge ruled that Pfizer can present expert testimony in an upcoming patent trial, which is expected to influence the availability of generic versions of tafamidis [1] - The ruling is seen as strengthening Pfizer's position against generic-drug makers attempting to invalidate its patent, which is set to last until 2035 [1] - Analysts suggest that this development could lead to a potential settlement, positively impacting BridgeBio's stock [1] Group 2: BridgeBio's Product and Sales Performance - BridgeBio's drug, Attruby, is experiencing strong sales growth, with at least double-digit sequential increases each quarter since its market entry [1] - Despite recent stock pullbacks, analysts remain optimistic about BridgeBio's continued commercial momentum and regulatory progress [1] - The preference of doctors for protein stabilizers like Attruby over competing treatments is noted, indicating a favorable market position for BridgeBio [1] Group 3: Stock Performance and Analyst Ratings - BridgeBio's stock rose by 13.2% to $74.32, surpassing its 50-day moving average, and holds a strong Relative Strength Rating of 90 [1] - Analysts from Barclays and JPMorgan express positive outlooks on BridgeBio's stock, with recommendations for overweight positions based on its growth potential [1]

Group 1 - William Blair initiated coverage on BridgeBio, emphasizing the company's expanding pipeline of treatments for rare genetic conditions [1] - Analyst John Boyle highlighted BridgeBio's unique position with an accelerating launch of Attruby and near-term NDA submissions for disease-modifying therapies, projecting launches in late 2026 to early 2027 [2] - Market surveys indicate that prescribers view Attruby and Amvuttra as superior next-generation products compared to the market leader, Pfizer's Tafamidis, which has annualized sales of approximately $6 billion [3] Group 2 - There is a potential risk from generic entry for BridgeBio in late 2028; however, the threat is considered lower than perceived due to Attruby's strong TTR stabilization and simple dosing regimen, which could support premium pricing [4] - The pivotal PROPEL 3 study data for infigratinib in achondroplasia shows a best-in-class efficacy profile with a favorable once-daily oral formulation, indicating meaningful differentiation in the market [5] - Significant market opportunities are also identified for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), with the CALIBRATE Phase 3 study meeting its primary endpoint in October 2025 [6]

Summary of BridgeBio's 2026 Conference Call Company Overview - **Company**: BridgeBio (NasdaqGS:BBIO) - **Event**: 2026 Leerink Partners Global Healthcare Conference - **Date**: March 10, 2026 Key Points TTR Market and Attruby Performance - **Patient Growth**: Accelerated from approximately 60 patients per week at launch to over 150 patients per week, indicating strong market acceptance [3][5] - **Market Dynamics**: The growth is attributed to: - Strong clinical data supporting Attruby as the first near-complete stabilizer for TTR [3] - Increased disease awareness and improved diagnosis through AI initiatives [4] - Broader prescriber base, particularly high-volume heart failure clinics [4][5] - **Market Share**: Achieved over 25% share in treatment-naive patients within a year of launch, with a goal of exceeding 30% [5] - **Pricing Stability**: Net pricing for Attruby remains stable, with gross-to-net ratios in the 30%-40% range [6][7] European Market and BEYONTTRA - **Partnership with Bayer**: Successful collaboration for the launch of BEYONTTRA, with over 50% treatment-naive share in Germany due to a single-payer system [9][10] - **Future Launches**: Upcoming launches planned in Denmark, Spain, Italy, and France, with royalties starting at 30% [11] Combination Therapy and Competitive Landscape - **Tafamidis IP Discussion**: Potential outcomes for tafamidis patent litigation could impact market dynamics, with expectations of generic entry possibly in the 2030s [12] - **Combination Therapy Insights**: Current data shows no significant benefits from combination therapies, with a focus on establishing Attruby as the most potent stabilizer [13][14] Pipeline Developments - **Depleter Program**: BridgeBio is developing an in-house depleter to complement Attruby, targeting the removal of monomers that cause cardiomyopathy [15][16][17] - **Achondroplasia Strategy**: Infigratinib is positioned as a superior oral treatment option, with a focus on market expansion through patient switches from injections [18][22][23] - **Global Launch Plans**: International strategy involves a phased approach, starting with Germany, with regulatory filings expected to lag behind U.S. timelines by 3-4 months [27][28] Financial Outlook and Margin Profile - **Cost Management**: R&D expenses are expected to remain flat, while SG&A expenses will increase due to upcoming launches [39] - **Margin Expectations**: Anticipated gross margins for new products could reach 70%-80%, with a significant increase in total operating spend as new products launch [50] Additional Insights - **Equity Stake in GondolaBio**: BridgeBio holds an equity stake in GondolaBio, an early-stage R&D engine, which may be integrated into future strategies [52] This summary encapsulates the critical insights and strategic directions discussed during the conference call, highlighting BridgeBio's growth trajectory, market strategies, and financial outlook.

Core Insights - BridgeBio Pharma, Inc. (NASDAQ:BBIO) is recognized as one of the 10 Fastest Growing NASDAQ Stocks to Buy [1] - Truist analyst Danielle Brill raised the price target for BBIO to $95 from $86, maintaining a Buy rating, citing a 35% increase in Q4 Attruby sales to $146 million [2] - Morgan Stanley analyst Sean Laaman increased the price target for BBIO to $98 from $96, reiterating an Overweight rating after the Q4 report [3] - BridgeBio reported Q4 EPS of ($1.00), missing consensus estimates of (67 cents), but revenue of $154.18 million exceeded the $149.07 million consensus [4] - CEO Neil Kumar highlighted the company's progress, noting three successful Phase 3 readouts in a short period and expressing optimism for six approved products as the company approaches its first decade [4] Financial Performance - Q4 revenue reached $154.18 million, surpassing the consensus estimate of $149.07 million [4] - Q4 Attruby sales were reported at $146 million, reflecting a 35% increase from Q3 [2] - The company reported a Q4 EPS of ($1.00), which was below the consensus estimate of (67 cents) [4] Analyst Ratings - Truist's price target for BBIO is now $95, up from $86, with a Buy rating maintained [2] - Morgan Stanley's price target for BBIO is now $98, increased from $96, with an Overweight rating reiterated [3]

Group 1: Financial Performance - BridgeBio Pharma reported a total revenue of $502.1 million for the full year 2025, driven by the commercial success of its flagship product, Attruby [1] - In Q4 2025, Attruby generated $146 million in net product revenue, reflecting a 35% increase over Q3 [1] - The company experienced a net loss of $724.9 million for the year, but expects cash burn to stabilize and decrease as Attruby's margins expand [4] Group 2: Product Development and Clinical Milestones - BridgeBio achieved three positive Phase 3 readouts in late 2025 for Encaleret, BBP-418, and Infigratinib, positioning the company to potentially have six approved medicines by the end of its first decade [2] - New Drug Applications (NDAs) for Encaleret and BBP-418 are expected in H1 2026, with US launches targeted for late 2026 or early 2027 [2] Group 3: Market Position and Competitive Landscape - Attruby's near-complete stabilization of transthyretin serves as a key clinical differentiator that should protect its market share against potential generic competitors for tafamidis [4]

Core Insights - BridgeBio Pharma's Attruby has shown strong growth, particularly among first-line patients, attributed to exceptional clinical data and effective field execution [1][4] - The company is transitioning from a focus on R&D spending to becoming a multi-product business with expected revenue growth and cash generation [3][5] Financial Performance - For Q4 2025, BridgeBio reported net product revenue of $146 million, contributing to a total revenue of $502.1 million for the full year, up from $221.9 million in 2024 [2][15] - The company ended 2025 with $587.5 million in cash and issued $632.5 million in convertible notes in January 2026, extending its financial runway [5][17] - Operating costs for Q4 2025 were $293.7 million, with full-year costs reaching $1.0 billion, primarily due to increased SG&A expenses related to the Attruby launch [16][17] Product and Pipeline Developments - Attruby has achieved over 25% market share in the MBRX category as of December 31, 2025, with 7,804 unique prescriptions written by 1,856 prescribers [2][7] - The company reported positive Phase 3 results for several late-stage programs, including encaleret, BBP-418, and infigratinib, with infigratinib meeting its primary endpoint with a p-value of <0.0001 [6][11] - Upcoming product launches for encaleret and BBP-418 are anticipated in late 2026 or early 2027 [14] Intellectual Property and Market Position - BridgeBio's commercial strategy for Attruby is considered independent of the intellectual property status of tafamidis, with management emphasizing clinical performance over IP concerns [8][9] - The company maintains a base case assumption for generic entry in Europe by 2030, while asserting that Vyndamax should have protection into the 2030s [9] Strategic Outlook - Management expects to transition from being cash-consumptive to generating significant cash flows by 2028, with the pipeline projected to start generating cash by late 2027 [5][17] - The company is focused on reinvesting in R&D to exceed its cost of capital, while also considering other capital allocation options such as buybacks or dividends if necessary [19]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $154.2 million, consisting of $146 million from Attruby net product revenue, compared to $5.9 million for the same period last year, reflecting a significant increase of $148.3 million [32][33] - For the full year 2025, total revenues reached $502.1 million, up from $221.9 million in 2024, driven primarily by a $359.5 million increase in net product revenue from Attruby [33][34] - Operating costs for Q4 2025 were $293.7 million, compared to $231.9 million in the same period last year, with a notable increase in SG&A expenses [34][35] Business Line Data and Key Metrics Changes - Attruby's net product revenue for Q4 was $146 million, contributing to a total of $362.4 million for the year, with new patient starts reaching 7,804 [24][32] - The company reported a 35% quarter-over-quarter growth in net product revenue for Attruby, indicating strong commercial momentum [24][25] Market Data and Key Metrics Changes - Attruby achieved over 25% market share in the ATTR cardiomyopathy market as of December 31, 2025, with continued growth in unique patient prescriptions [18][24] - The company noted that the adoption of Attruby is accelerating, particularly in first-line patients, surpassing previous expectations [25][30] Company Strategy and Development Direction - The company is transitioning from a cash-consuming business to one that generates significant cash flows, with expectations of cash generation starting in late 2027 and becoming a cash generation engine by 2028 [8][9] - The focus remains on advancing three additional product candidates towards commercialization, with a strong emphasis on maintaining a best-in-class commercial engine for genetic diseases [10][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's fundamentals, despite recent stock volatility, and emphasized the intrinsic value of BridgeBio is increasing [11][12] - The company is actively evaluating options to ensure shareholder value is recognized, with over $1 billion in capital available to support its strategic initiatives [12][36] Other Important Information - The company has successfully completed three late-stage readouts, marking a transformative inflection point for BridgeBio [4][5] - Management highlighted the importance of clinical data in driving market share and emphasized the differentiated profile of Attruby compared to competitors [10][23] Q&A Session Summary Question: What drives Attruby's consistent growth despite competitors slowing down? - Management attributed growth to a strong field team, superior clinical data, and a disciplined focus on patient needs, leading to high adoption rates [39][41] Question: When will significant real-world data be available to establish clinical differentiation? - Management indicated that real-world evidence should be available by the end of the year, focusing on early impact and specific patient populations [51][52] Question: How does the company plan to use incremental free cash flow in the future? - The strategy includes reinvesting in R&D and potentially considering share buybacks or dividends if intrinsic value is not reflected in stock price [54][55] Question: Can you elaborate on launch readiness and expected regulatory catalysts? - The company plans to follow rigorous launch protocols similar to Attruby, with a focus on global launches and setting new standards of care [60][62] Question: What is the outlook on tafamidis IP and its impact on Attruby? - Management believes the tafamidis IP situation is a sideshow and does not impact Attruby's uptake, as the differentiated clinical data continues to drive momentum [78][83]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $154.2 million, consisting of $146 million from Attruby net product revenue, compared to $5.9 million for the same period last year, reflecting a significant increase of $148.3 million [32][33] - For the full year 2025, total revenues reached $502.1 million, up from $221.9 million in 2024, marking an increase of $280.2 million [33] - Operating costs for Q4 2025 were $293.7 million, compared to $231.9 million in the same period last year, driven primarily by a $63.3 million increase in SG&A expenses [34] Business Line Data and Key Metrics Changes - Attruby's net product revenue for Q4 was $146 million, contributing to a total of $362.4 million for the year, with a 35% quarter-over-quarter growth in net product revenue [24][32] - The number of unique patient prescriptions for Attruby reached 7,804, with 1,856 unique prescribers as of February 20, 2026, indicating strong commercial momentum [18][24] Market Data and Key Metrics Changes - Attruby achieved over 25% market share in the ATTR cardiomyopathy market as of December 31, 2025, with continued growth in first-line patient adoption [18][24] - The company anticipates that its pipeline will generate cash in late 2027 and become a cash generation engine by 2028, projecting over $600 million in profit by that year [9][10] Company Strategy and Development Direction - The company is transitioning from a cash-consuming business to one that generates significant cash flows, with a focus on launching three additional products while maintaining steady cash burn [8][9] - The strategy emphasizes establishing a best-in-class commercial engine for genetic disease therapies, leveraging strong clinical data and market positioning [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's fundamentals, despite recent stock volatility, and highlighted the disconnect between intrinsic value and market valuation [11][12] - The company is focused on executing against milestones and believes its intrinsic value has increased due to recent clinical successes [11][12] Other Important Information - The company ended the year with a cash position of $587.5 million and completed the issuance of $632.5 million in convertible notes, providing a strong cash runway for future operations [36] - Management noted that the recent volatility in stock price is primarily due to uncertainty surrounding the Tafamidis IP situation, but they remain confident in Attruby's clinical profile and market positioning [20][22] Q&A Session Summary Question: What are the key drivers behind Attruby's consistent growth despite competitors slowing down? - Management attributed growth to a strong field team, superior clinical data, and a disciplined focus on patient and healthcare professional needs [41][42] Question: When will significant real-world data be available to establish clinical differentiation? - Management indicated that real-world evidence should be available by the end of the year, focusing on early impact and outcomes related to atrial fibrillation [51] Question: How does the company plan to utilize incremental free cash flow in the future? - The company plans to reinvest in R&D and potentially consider share buybacks or dividends if unable to capture the intrinsic value of its assets [54][55] Question: What is the launch readiness for the upcoming products? - The company is preparing for global launches, building on the successful launch of Attruby, and expects to set new standards of care with upcoming products [60][61]